Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, detailed methods for generating, maintaining, and characterizing human pluripotent stem cell-derived small intestinal and colonic organoids are described. These methods are designed to improve reproducibility, expand scalability, and decrease the working time required for plating and passaging of organoids.

Abstract

Intestinal regional specification describes a process through which unique morphology and function are imparted to defined areas of the developing gastrointestinal (GI) tract. Regional specification in the intestine is driven by multiple developmental pathways, including the bone morphogenetic protein (BMP) pathway. Based on normal regional specification, a method to generate human colonic organoids (HCOs) from human pluripotent stem cells (hPSCs), which include human embryonic stem cells (hES) and induced pluripotent stem cells (iPSCs), was developed. A three-day induction of BMP signaling sufficiently patterns mid/hindgut tube cultures into special AT-rich sequence-binding protein 2 (SATB2)-expressing HCOs containing all of the main epithelial cell types present in human colon as well as co-developing mesenchymal cells. Omission of BMP (or addition of the BMP inhibitor NOGGIN) during this critical patterning period resulted in the formation of human intestinal organoids (HIOs). HIOs and HCOs morphologically and molecularly resemble human developing small intestine and colon, respectively. Despite the utility of HIOs and HCOs for studying human intestinal development, the generation of HIOs and HCOs is challenging. This paper presents methods for generating, maintaining, and characterizing HIOs and HCOs. In addition, the critical steps in the protocol and troubleshooting recommendations are provided.

Introduction

Studying human colon development is difficult due to restrictions on the use of human fetal tissue. Animal models have been invaluable and historically used for genetic approaches in mice to study intestinal development. However, differences between mouse and human intestinal development limit the applicability of mice as a model system. For instance, although crypt formation in the small intestine and colon of mice occurs postnatally, humans are born with fully formed crypts1. Furthermore, the human small intestine and colon contain cell types that are not found in mice, including motilin (MLN)-expressing enteroendocrine cells in the small int....

Protocol

1. Generation of human intestinal and colonic organoids

  1. Preparing ECM-coated plates
    1. Add 50 mL of cold DMEM medium into a 50 mL conical tube.
    2. Remove an aliquot of 4x hESC-qualified ECM (see the Table of Materials) from the -80 °C freezer and thaw on ice.
      NOTE: Refer to the product's certificate of analysis to determine the volume of ESC-qualified ECM required to prepare a 4x stock.
    3. If hESC-qualified ECM is not fully thawed, take 750 µL of.......

Representative Results

The successful generation of spheroids during the mid/hindgut induction stage is indicative of successful patterning. Perform IF staining for CDX2 on floating spheroids and on the monolayer to confirm that patterning is correct. Although staining at the definitive endoderm (DE) stage can indicate the effectiveness of DE induction, spheroid generation is not possible without efficient DE induction. To test the efficiency of DE induction, perform IF staining and/or RT-qPCR for FOXA2 and SOX17.

F.......

Discussion

The differentiation of hPSCs into HIOs and HCOs is a complex process requiring quality controls at each step. The starting hPSCs need to have minimal differentiation before initiating differentiation into DE. Optimizing the density of hPSCs plated for DE differentiation is critical for the success of the protocol. To ensure the quality of DE differentiation, perform IF for FOXA2 and SOX17 to determine the efficiency of DE differentiation. DE differentiation should result in over 80% of the treated cells staining positive.......

Acknowledgements

The Múnera lab is funded by NIH/NCI 5U54CA210962-02 South Carolina Cancer Disparities Research Center (SC CADRE), NIH/NIGMS P20 GM130457-01A1 COBRE in Digestive and Liver Disease, and NIH/NIDDK 1P30 DK123704-01 MUSC Digestive Disease Research Core Center.

....

Materials

NameCompanyCatalog NumberComments
1% Bovine serum albumin (BSA) solutionN/AN/AN/A
15 mL Corning tubeFalcon21008-918N/A
30% SucroseN/AN/AMade in PBS.
5% Normal donkey serumJackson ImmunoResearch Lab017-000-121N/A
50 mL Corning tubeFalcon21008-951N/A
AccutaseThermo ScientificA1110501Cell detachment solution; aliquot 5 mL of Accutase into 10 mL tubes totaling 20 tubes and store at -20 °C for up to 6 months. Place at 4 °C overnight before use.
Activin ACell guidance SystemsGFH6-100x10Reconstitute the lyophilized powder at 100 µg/mL in sterile PBS containing 0.1% bovine serum albumin (BSA). Aliquot 38 µL of Activin A into prechilled microcentrifuge tubes and store at -80 °C (Tubes expire 12 months from date of receipt).
Activin Day 1 medium (RPMI 1640)CorningMT10041CVUse nonessential amino acids (NEAA, Corning 11140050) and store at 4 °C. Basic day 1 medium: 500 mL of RPMI 1640 and 500 mL of NEAA. When preparing Activin Day 1 medium, add 13 mL of basic day 1 medium, 13 µl of Activin A (100 µg/mL), and 2 µl of BMP4 (100 µg/mL). The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
Activin Day 2 medium (RPMI 1640, 0.2% FBS vol/vol)HycloneSH30070.03TUse nonessential amino acids (Corning 11140050) and store at 4 °C. Basic day 2 medium: 500 mL of RPMI 1640, 500 mL of NEAA, and 1 mL of 0.2% serum. When preparing Activin Day 2 medium, add 12.5 mL of basic day 2 medium and 12.5 µL of Activin A (100 µg/mL). The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
Activin Day 3 medium (RPMI 1640, 2% FBS vol/vol)HycloneSH30070.03TUse nonessential amino acids (Corning 11140050) and store at 4 °C. Basic day 3 medium: 500 mL of RPMI 1640, 500 mL NEAA, and 10 mL of 2% serum. When preparing Activin Day 3 medium, add 12.5 mL of basic day 3 and 12.5 µL of Activin A (100 µg/mL). The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
Alexa Fluor 488 Donkey anti-GoatThermo ScientificA110551:500 dilution (Secondary antibody)
Alexa Fluor 488 Donkey anti-RabbitThermo ScientificA212061:500 dilution (Secondary antibody)
Alexa Fluor 546 Donkey anti-MouseThermo ScientificA100361:500 dilution (Secondary antibody)
Alexa Fluor 647 Donkey anti-MouseThermo ScientificA315711:500 dilution (Secondary antibody)
Base moldFisher22-363-552N/A
Basic gut medium (advanced DMEM)Gibco12491015 When preparing Basic gut medium, add 500 mL of DMEM, 500 mL of N2 (Gibco 17-502-048), 500 mL of B27 (Gibco), 500 mL of L-Glutamine to get 2 mM L-Glutamine (Corning A2916801), 5 mL of 100 U/mL Penicillin-Streptomycin (Gibco 15-140-122), and 7.5 mL of  1 M HEPES to get 15 mM HEPES.  The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
Biorad CFX96 Touch Real-Time PCR Detection SystemBioradN/AOther qRT-PCR systems can be used.
Cell Recovery SolutionCorning354253ECM-degrading solution
CHIR99021Reprocell4000410Reconstitute by adding 2.15 mL of DMSO at 10 mM. Prepare 50 µL aliquots and store at -20 °C.  Store powder at 4 °C, protected from light.
CTRL HIO patterning mediumN/AN/ABasic gut medium and 100 ng/mL EGF.
DAPISigma-AldrichD95421:100 dilution (Secondary antibody)
DE monolayerN/AN/AMonolayer was generated in prior steps (Section 4.4).
DispaseGibco17105041Resuspend lyophilized powder in Advanced DMEM (Gibco MT15090CV) to a 1 mg/mL final concentration. Filter the solution for sterilization by vacuuming using a Millipore filter sterilization tube. Make 10 mL aliquots (1 mg/mL) and store at -20 °C for up to 6 months. Place at 4 °C overnight before use.
EGFThermo Scientific236-EG-01MWhen preparing 100 ng/mL EGF reconstitute 500 µg/mL in sterile PBS. Next add 2 mL of sterile PBS to 1 mg EGF and make 500 µg/mL EGF solution. Aliquot 100 µL of EGF in 20 tubes.
Fisherbrand 6 cm Petri Dishes with Clear LidFisherFB0875713AN/A
Fisherbrand Cell LifterFisher08-100-240N/A
Fisherbrand Class B Clear Glass Threaded Vials with Closures AttachedFisher03-338BN/A
Fisherbrand Disposable Borosilicate Glass Pasteur PipetteFisher13-678-2D0N/A
Fluoromount G Slide Mounting MediumVWR100241-874N/A
Gibco advanced DMEMGibco12-491-023N/A
Goat anti-E-CadherinR&D systemsAF6481:400 dilution (Primary antibody)
Goat anti-SOX17R&D systemsAF19241:500 dilution (Primary antibody)
HCOs patterning mediumN/AN/ABasic gut medium, 100 ng/mL EGF and 100 ng/mL BMP2. When preparing BMP2, add 1 mL of sterile 4 mM HCl 0.1% BSA to BMP2 vials (100 µg). Aliquot 25 µL of BMP4 solution in 4 tubes.  The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
HemocytometerSigma-AldrichZ359629N/A
Human Pluripotent Stem Cells (hPSC)Pluripotent Stem Cell FacilityN/ACells seeded in a Matrigel coated 24-well plate (Thermo Scientific 73520-906).
Ice-cold 4% Paraformaldehyde solution (PFA)N/AN/AN/A
Ice-cold Phosphate Buffered Saline (PBS)N/AN/AThe pH must be 7.4.
ImmEdge Hydrophobic Barrier PenVector Laboratories101098-065N/A
Induced Pluripotent Stem Cells (iPSCs)Pluripotent Stem Cell Facility (Cincinnati Children's Hospital Medical Center)N/AOther hESC or iPSC lines can be used, but the protocol needs to be optimized for each cell line.
Leica microtomeN/AN/AN/A
LSM 880confocal microscope
Matrigel Basement Membrane MatrixCorning354234N/A
Matrigel hESC-qualified MatrixCorning354277Prepare 4 x Matrigel aliquots which corresponds to volumes sufficient to make enough diluted Matrigel for 4 x 6-well dishes.
Mid-hindgut induction medium (RPMI 1640)CorningMT10041CVNonessential amino acids (Corning 11140050), 2% FBS vol/vol (Hyclone SH30070.03T), 3 µM CHIR99021 and 500 ng/mL FGF4. The base medium is stable for up to 3 weeks but should be used immediately after addition of growth factors.
Mid-hindgut spheroidsN/AN/AN/A
MilliporeSigma Steriflip Sterile Disposable Vacuum Filter UnitsMilliporeSigmaSCGP00525N/A
Mouse anti-CDX2BioGenexMU392-UC1:300 dilution (Primary antibody)
Mouse anti-FOXA2Abnova/NovusH00003170-M011:500 dilution
mTeSR1 complete growth mediumStem Cell technologies85870Add 100-mL of mTeSR supplement (85870) into one 400-mL mTeSR medium (85870) and aliquot into 50-mL tubes while avoiding contamination. Store at 4°C until use.
Murray's Clear solution (Also known as BABB)Murray'sN/A1:2 benzyl benzoate and benzyl alcohol.
NOG HIO patterning mediumN/AN/ABasic gut medium, 100 ng/mL EGF and 100 ng/mL NOGGIN (Dispense 25 µg of NOGGIN in 250 µl sterile PBS with 0.1% BSA).
NucleoSpin RNATakara740955.25Other RNA isolation kits may be used.
Nunclon delta surface tissue culture dish 24-wells (Nunc)Thermo Scientific73521-004N/A
Nunclon delta surface tissue culture dish 24-wells coated with MatrigelThermo Scientific73521-004N/A
Nunclon delta surface tissue culture dish 6-wells (Nunc)Thermo Scientific73520-906N/A
Nunclon delta surface tissue culture dish 6-wells coated with  Matrigel.Thermo Scientific73520-906N/A
Outgrowth medium for HIOs, CTRL HIOs, and HCOsN/AN/ABasic gut medium and 100 ng/mL EGF (Final concentration)
Phosphate Buffer Saline, 0.5% Triton X (PBS-T)N/AN/AN/A
PrimersIntegrated DNA Technologies, Inc. (IDT)N/AThe primers are listed in Table 2 on the protocol.
Rabbit anti-CDX2Cell MarqueEPR22764Y1:100 dilution (Primary antibody)
Rabbit anti-SATB2Cell MarqueEP2811:100 dilution (Primary antibody)
Recombinant Human BMP-4 ProteinR&D systems314-BP-010Reconstitute the lyophilized powder at 100 µg/mL in sterile 4 mM HCl containing 0.1% bovine serum albumin (BSA). Add 4.17 mL HCl solution to 45.83 mL molecular water totaling to 50 mL of 1 M HCl. Then add 200 µL of 1 M HCl to 49.8 mL of molecular grade water totaling to 50 mL of 4 mM HCl. Next add 0.05 g BSA to 50 mL of 4 mM HCl and filter to make sterile. Aliquot sterile 4 mM HCl 0.1% BSA to 33 microcentrifuge tube totaling and store at -20 °C. Add 100 µl of sterile 4 mM HCl 0.1% BSA to the BMP4 vials (10 µg) to make BMP4 solution at 100 µg/mL.
Recombinant Human FGF-4 ProteinR&D systems235-F4-01MReconstitute at 100 µg/mL in sterile PBS containing 0.1% bovine serum albumin. Add 0.05 g of BSA in 50 mL of PBS to make 0.1% BSA. Filter 0.22 µM BSA to sterilize the BSA. Aliquot 10 mL of 0.1% BSA in 5 tubes. Add 1 mg FGF-4 in 10 mL of sterile 0.1% BSA. Aliquot 250 µL into prechilled 40 microcentrifuge tubes and store at -80 °C.
ROCK inhibitor Y-27632Tocris1254The final concentration is 10 mM (10 mmol/L). Resuspend in DMSO at 10 mM and filter sterilize. Add 3 mL of sterile PBS to each vial. Aliqout 100 µL of ROCK inhibitor in 30 tubes and store at -20 °C.
SuperScript VILO cDNA Synthesis KitThermo Scientific11-754-250N/A
SuperFrost Plus microscope slides
Tissue Tek O.C.T CompoundVWR25608-930N/A

References

  1. Montgomery, R. K., Mulberg, A. E., Grand, R. J. Development of the human gastrointestinal tract: twenty years of progress. Gastroenterology. 116 (3), 702-731 (1999).
  2. Beumer, J., et al. High-resolution mRNA a....

Explore More Articles

Human Pluripotent Stem CellsIntestinal OrganoidsColonic OrganoidsGastrointestinal DevelopmentRegional SpecificationBMP SignalingSATB2Epithelial Cell TypesMesenchymal CellsIntestinal DevelopmentColon DevelopmentOrganoid GenerationOrganoid Characterization

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved